117 results
8-K
EX-99.2
MRNS
Marinus Pharmaceuticals Inc
5 Mar 24
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
4:05pm
Reimbursement pathways 250ml exclusive offering Access, reimbursement & informatics support Launch prioritization Focus on key accounts to enable … /Reimbursement Driving awareness through disease state education Initiate education to payors on RAISE and target hospital formulary decision makers
8-K
EX-99.2
MRNS
Marinus Pharmaceuticals Inc
4 Jan 24
Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY® Net Product Revenue and Provides Business Update
7:04am
Support for Rapid Uptake Accelerated Access Strategy Distribution & Channel Reimbursement pathways 250ml exclusive offering Access, reimbursement … and Orion (EU) R&D Reimbursement Orion (EU) Royalty and Milestones1 $Oaktree Capital Tenacia (China) Royalty and Milestones2 $ BARDA3 & Other Global Partnerships Actively Pursuing Biologix (MENA) Revenues and Milestones2 $
8-K
EX-99.1
aiok vqmm
28 Nov 23
Other Events
7:05am
8-K
EX-99.2
re17e4i34gp91bdri2r
7 Nov 23
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results
7:11am
8-K
EX-99.1
3hyy1ye jfs3ho
28 Sep 23
Other Events
7:05am
8-K
EX-99.1
pqrkfmg
19 Sep 23
Marinus Pharmaceuticals Highlights Advancing Pipeline and Commercial Strategy at Investor and Analyst Event
8:02am
8-K
EX-99.2
xkuf bwgj
10 Aug 23
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results
7:10am
8-K
EX-99.1
couc qk4cdmc1kdmdf1y
1 Aug 23
ZTALMY is the first treatment approved by the European Commission for seizures associated with CDKL5 deficiency disorder in children and adolescents
4:05pm
8-K
EX-99.2
j3wn1k96i3258xlm7o
11 May 23
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results
7:03am
8-K
EX-1.1
dqospez
10 Nov 22
Marinus Pharmaceuticals Announces Proposed Public Offering
7:26am